amcure, a company that received support from Ascenion’s Spinnovator coaching program from the beginning, reports a significant milestone: At the end of October the company initiated a Phase I/Ib study with its lead programme AMC303 in cancer patients. The first patient has already been treated. The study is designed to assess the safety, tolerability and pharmacokinetics of multiple and increasing doses of AMC303 as a monotherapy in patients with advanced metastatic tumours of epithelial origin, for example pancreatic, head and neck, colorectal, gastric and lung cancer.
AMC303 provides a potential novel mechanism for the treatment of advanced tumours. It specifically binds to CD44v6, an important co-receptor in several cellular signalling pathways involved in tumour growth and metastases.
To continue and accelerate the clinical development of AMC303, the company was able to secure Euro 6 Million from a consortium of existing investors and shareholders, which brings the total amount of capital raised by amcure to Euro 10 million. Additionally, amcure expanded its advisory board by appointing renowned Dr. Bruno Osterwalder, who brings in additional industry and disease expertise.
For further information:
press release amcure "start clinical study"
press release amcure "Series B Financing "